This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Hospital Remove Nuclear Medicine Remove Patient Safety Remove Radiopharmaceuticals
article thumbnail

ARRS: How to manage the side effects of radiopharmaceuticals

AuntMinnie

MAY 8, 2024

Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. In addition, dose calculations estimated mean dose to the arm of approximately 3 Gy.

Radiopharmaceuticals 75
Radiopharmaceuticals Nuclear Medicine Radiation Hospital 75
article thumbnail

SNMMI Elects Jean-Luc C. Urbain, MD, PhD, FASNC, as President-Elect at 2024 Annual Meeting

Imaging Technology

JUNE 10, 2024

Urbain, MD, PhD, FASNC, professor of Radiology/Nuclear Medicine and Medicine, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). I look forward to working with all SNMMI members, stakeholders, and patients ‘communities to achieve these goals.”

Nuclear Medicine 59
Nuclear Medicine Radiopharmaceuticals Hospital Health Science 59
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 5,000 Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024